Pittsford, NY, United States of America

Kyle D Monroe

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 46(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: **Kyle D Monroe - Innovator in PCSK9 Biology**

Introduction

Kyle D Monroe, based in Pittsford, NY, is a prominent inventor known for his significant contributions to the field of PCSK9 biology. With a remarkable portfolio of 13 patents, Monroe has developed innovative solutions aimed at modulating the activity of the PCSK9 protein, which plays a critical role in cholesterol metabolism and cardiovascular health.

Latest Patents

Monroe's latest inventions include two notable patents concerning small organic compounds that target PCSK9 protein activity. The first patent focuses on the "Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity." This invention explores how these small molecules can influence the conformation of the PCSK9 protein, thereby affecting levels of low-density lipoproteins (LDL) in circulation. High LDL-cholesterol levels are linked to an elevated risk of heart disease, while low levels can lead to complications in other conditions, such as liver dysfunction.

The second patent, "Phenylalanine small organic compounds to directly modulate PCSK9 protein activity," further expands on the use of small organic compounds as ligands for PCSK9 modulation. Like the first, this invention provides insights into how modifying the interaction between PCSK9 and low-density lipoprotein receptors can lead to either increased or decreased LDL-cholesterol levels.

Career Highlights

Kyle D Monroe has earned recognition for his work at Srx Cardio, LLC and Sxr Cardio, LLC, where he has focused on developing therapeutic strategies to address cholesterol-related health issues. His patents not only contribute to scientific advancement but also hold potential for real-world applications that can improve therapeutic outcomes for patients at risk of heart disease.

Collaborations

Throughout his career, Monroe has collaborated with notable professionals, including his coworkers Michael Mark Muehlemann and Thomas E Barta. Their joint efforts reflect a shared commitment to advancing research and development within the biotechnology sector.

Conclusion

Kyle D Monroe’s innovative approach to PCSK9 biology highlights the importance of scientific research in tackling health challenges related to cholesterol management. With a robust portfolio of patents and collaborative efforts, Monroe continues to pave the way for advancements that could ultimately lead to improved health outcomes for individuals affected by cardiovascular diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…